Biotech Startups
9,833 companies tagged Biotech, with their investors and founders.
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas. The company is backed by multiple life sciences investment firms and operates from San Diego.
3 investors
Forty Seven Inc was a clinical-stage immuno-oncology company developing antibody therapies targeting CD47, a "don't eat me" signal exploited by cancer cells, with lead candidate magrolimab. Acquired by Gilead Sciences in 2020.
3 investors
FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors. Its work centers on cancer therapeutics developed by a team with pharma and biotech backgrounds.
3 investors
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms. The company serves patients and the physician community seeking alternatives to lifelong pharmaceutical treatments.
3 investors
GAIA BioMedicine (ζ ͺεΌδΌη€Ύγ¬γ€γ’γγ€γͺγ‘γγ£γ·γ³) develops GAIA-NK, a cell therapy using engineered cells with high cytotoxic activity against solid tumors, based on research from Kyushu University. The company researches, develops, and manufactures regenerative medicine products aimed at curative cancer treatment.
3 investors
Gandeeva Therapeutics uses AI, machine learning, and atomic-resolution cryo-EM imaging to map druggable protein interactions and design molecular glues that bind at specific protein interfaces. The company applies this drug-discovery approach to develop precision medicines against targets such as protein-protein complexes, nucleic acid-protein complexes, and membrane proteins.
3 investors
Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
3 investors
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFomeβ’ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling. The platform is designed to expand patient access to cell therapies across various therapeutic areas.
3 investors
Gelatex Technologies develops nanofiber production technology for use in food production, medical applications, and sustainable materials. The company focuses on creating materials with lower environmental impact across multiple industrial sectors.
3 investors
Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
3 investors
Skyline Therapeutics develops gene therapy vector technology and supports clinical development for therapeutic applications using genetic science approaches.
3 investors
Genemod offers a lab management platform that combines electronic lab notebook (ELN), LIMS, inventory, and equipment tracking in one data model, with AI agents that plan experiments, execute protocols across connected systems, and generate audit-ready records. It serves scientific research teams ranging from discovery labs to regulated manufacturing, including protein therapeutics, cell line development, strain design, and academic labs.
3 investors
General Biological converts agricultural feedstock into high-value industrial chemicals at a bio-based manufacturing facility on the Mississippi River in Northeast Louisiana. It aims to rebuild a domestic U.S. chemical supply chain for critical industrial molecules using stranded agricultural infrastructure.
3 investors
General Sense develops detection technology that augments trained detection animals, aiming to identify molecular threats such as narcotics, crop diseases, human diseases, and bioweapons. It offers higher sensitivity and objective digital readouts to make detection a passive, more reliable task than relying on traditional detection dogs alone.
3 investors
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
3 investors
Genialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
3 investors
Genie Fertility develops a discovery platform that uses machine learning and multi-omics analysis to identify molecular biomarkers in uterine lining, leveraging menstrual blood samples to improve reproductive health outcomes and fertility diagnostics. The platform aims to address the high failure rate of IVF by providing better understanding of endometrial health, which can account for up to one-quarter of infertility issues.
3 investors
Geninus develops IntelliMed, a platform that uses multimodal spatial transcriptomics and patient data to discover novel drug targets for oncology, particularly for modalities like TCEs and ADCs. The platform combines spatial genomics, protein profiling, and clinical outcomes to enable target discovery with reduced biological risk.
3 investors
Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.
3 investors
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
3 investors
Genomic Health develops diagnostic tests and related services and runs health-equity initiatives aimed at improving access, awareness, and outcomes for patients and communities, including uninsured and underinsured populations. The company focuses on making its tests inclusive through diverse clinical trials, patient education, and community partnerships.
3 investors
GlycosBio conducts research and development using engineered lipid technologies to improve the bioavailability and therapeutic performance of natural bioactive molecules, including approaches targeting the intestinal, pulmonary, and skin microbiota. It works with clients on collaborative R&D, clinical validation, and IP licensing of its patented technologies, with research based at the Texas Medical Center in Houston.
3 investors
A pharmaceutical company that markets a portfolio of drug products across various dosage forms, with labeling and packaging following FDA requirements. Its products and prescribing information are registered under labeler codes 60429 and 51407 and listed on DailyMed.
3 investors
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.
3 investors